FDAsafety guidance84% confidence
Phase 1 IND Guidance Documents
Source: FDA
Why This Matters
Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to gene therapy companies; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Genetics · Gene Therapy
- Sub-indication
- General
Related signal: FDA Draft Guidance Aims to Accelerate Gene Therapy Development